Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Acrivon Therapeutics Inc
ACRV
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.82
0.03
1.67%
Últ. Act.: Oct 21, 4:14 PM
$1.89
0.091
5.07%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Acrivon Therapeutics Financials
Acrivon Therapeutics (ACRV) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share
Benzinga Newsdesk
PRO
Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of $(0.51) per share
Benzinga Newsdesk
PRO
Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses of $(0.60) per share
Benzinga Newsdesk
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
Avi Kapoor
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
Avi Kapoor
PRO
Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses of $(0.59) per share
Benzinga Newsdesk
